Ticker Hub
CRMD — AI Analysis & Sentiment
3 recent AI-generated analyses for CRMD. Sentiment and confidence insights updated continuously.
Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
CorMedix delivered strong Q1 results, exceeding expectations and raising full-year guidance, driven by product demand and pipeline progress. This f...
May 14, 2026CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients
CorMedix's positive Phase III REZZAYO results for expanded prophylaxis use significantly enhances its market potential. This strengthens the compan...
Apr 27, 2026CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
CorMedix reported strong Q4 and FY 2025 financial results, driven by growth in DefenCath and Melinta portfolio integration. The company is position...
Mar 5, 2026